PETACH TIKVA

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 8, 2024
SHIELD, Patient, Cancer, Research, New Drug Application, Marketing, Interim analysis, PIPE, Conference, Completeness, G&A

PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2024.

Key Points: 
  • Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024
    PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2024.
  • Top-line results are anticipated in the second half of 2024.
  • The Company’s cash runway now extends into the fourth quarter of 2024 and beyond the expected timing of the planned unblinded interim analysis.
  • PolyPid expects that its pro forma cash balance will be sufficient to fund operations into the fourth quarter of 2024.

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

Retrieved on: 
Wednesday, April 24, 2024
Conference, Webcast

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024.

Key Points: 
  • PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024.
  • The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
  • To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call.
  • For those not planning to ask a question of management, the Company recommends listening via the webcast.

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 28, 2024
Barclays, Conference

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.

Key Points: 
  • PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.
  • The PolyPid management team will participate in one-on-one investor meetings during this event.
  • Investors interested in meeting with PolyPid around the conference should contact their Barclays representative.

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 14, 2024
SHIELD, Marketing, Research, New Drug Application, Interim analysis, Completeness, PLEX, Conference, Monoclonal antibody, Dicarboxylic acid, Patient, Survival, PIPE, G&A, Pharmaceutical industry

Financial results for the full year ended December 31, 2023

Key Points: 
  • Financial results for the full year ended December 31, 2023
    R&D expenses, net for the year ended December 31, 2023, were $16.1 million, compared to $28 million in 2022.
  • G&A expenses for the year ended December 31, 2023, were $5.5 million, compared to $8.0 million for 2022.
  • Marketing and business development expenses for the year ended December 31, 2023, were $1.2 million, compared to $2.9 million for 2022.
  • PolyPid expects that its pro forma cash balance will be sufficient to fund operations into late third quarter 2024.

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Retrieved on: 
Monday, February 12, 2024
SHIELD, Late, Infection, New Drug Application, Interim analysis, Completeness, Patient, PIPE, Pharmaceutical industry

PETACH TIKVA, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled and randomized the 100th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. There are currently approximately 40 centers open.

Key Points: 
  • There are currently approximately 40 centers open.
  • The Company intends to conduct an unblinded interim analysis once a total of approximately 400 patients complete their 30-day follow-up, which is expected to occur in mid-2024.
  • “As anticipated, since last November, we have doubled the number of open centers, and enrollment into SHIELD II has recently begun to ramp-up,” said Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer.
  • The PIPE syndicate was comprised of new and existing investors, including participation from new U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors.

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

Retrieved on: 
Wednesday, January 31, 2024
Webcast, Conference

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024.

Key Points: 
  • PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024.
  • The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
  • To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call.
  • For those not planning to ask a question of management, the Company recommends listening via the webcast.

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Retrieved on: 
Thursday, January 4, 2024
SHIELD, Exercise, Sale, Data monitoring committee, Clinical trial, Calendar, Infection, Patient, Common stock, PIPE, Security (finance)

The PIPE syndicate is comprised of new and existing investors, including participation from new U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors.

Key Points: 
  • The PIPE syndicate is comprised of new and existing investors, including participation from new U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors.
  • The investors will also receive warrants to purchase up to 3,371,312 Ordinary Shares at an exercise price of $5.50 per share.
  • Exercise of the warrants in full would result in an additional $18.5 million in gross proceeds to the Company.
  • JMP Securities, A Citizens Company, is acting as exclusive placement agent in the offering.

Manuka Announces Review of Strategic Alternatives

Retrieved on: 
Thursday, November 16, 2023
Sale, Disclosure, Special-purpose acquisition company, OTCQB, Annual report, Risk, OTC Markets Group, Capital market, OTC, Security (finance), Manuka

Petach Tikva, Israel, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Manuka, Inc. ("Manuka" or the "Company") (OTCPINK:MNKA), a beauty company that develops and distributes premium-quality skincare products that are based on Manuka honey and bee venom, announced today that following a review of its business, resources and capabilities, it is exploring strategic alternatives focused on maximizing stockholder value.

Key Points: 
  • Petach Tikva, Israel, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Manuka, Inc. ("Manuka" or the "Company") (OTCPINK:MNKA), a beauty company that develops and distributes premium-quality skincare products that are based on Manuka honey and bee venom, announced today that following a review of its business, resources and capabilities, it is exploring strategic alternatives focused on maximizing stockholder value.
  • As part of this process, the Company has engaged ACP Capital Markets LLC (“ACP”) as an advisor to the Company in this process.
  • Strategic alternatives being evaluated include the sale of all or part of the Company, merger or reverse merger.
  • For example, Manuka is using forward-looking statement in this press release when it discusses strategic alternatives being evaluated or when it discusses the potential listing of Manuka’s shares on the OTCQB.

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
SHIELD, Research, American College, Good, Financial result, Good manufacturing practice, MD, G&A, Conference, MBA, Polypide, R, Canadian International Council, Marketing, Animal, GMP, Patient, PLEX, International Journal of Toxicology, Rare-earth element, Pharmaceutical industry, Nursing, Medical device, Fine chemical, Clothing, Cryptocurrency, Toxicology, EU

PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2023.
  • Presented the results of the SHIELD I Phase 3 trial for the first time at a medical meeting, the American College of Surgeons Clinical Congress 2023.
  • Financial results for nine months ended September 30, 2023
    R&D expenses, net for the nine months ended September 30, 2023, were $11.6 million, compared to $23.3 million for the same nine-month period of 2022.
  • PolyPid expects that this cash balance will be sufficient to fund operations into late first quarter of 2024.

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
M.B.A, Perioperative, International, Kellogg-HKUST Executive MBA Program, Christianity in Singapore, Sheba Medical Center, Tel Aviv University, Polypide, R, Business administration, Partnership, Internal medicine, Medical device, Management, Sanofi

“We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board.

Key Points: 
  • “We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board.
  • She has had a distinguished career as a practicing physician, biopharmaceutical industry executive and sector investor,” said Jacob Harel, PolyPid’s Chairman.
  • I would also like to thank Anat for her distinguished service and counsel as a member of PolyPid’s Board since April 2008.
  • In her most recent role at Sanofi, she served as Global Established Products Medical Lead – Strategic Decision for Portfolio Enhancement.